Alnylam Pharmaceuticals (ALNY) ROE - Return on Equity
Current and historical Return on Equity (ROE) values for Alnylam Pharmaceuticals (ALNY) over the last 10 years.
|Medical||Medical - Biomedical and Genetics||$12.272B||$0.090B|
|Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.|